Quaglino, Pietro

Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression

Sanlorenzo, M., Vujic, I., Daud, A., Algazi, A., Gubens, M., Luna, S. A., Lin, K., Quaglino, P., Rappersberger, K., & Ortiz-Urda, S. (2015) · JAMA Dermatology

Cancer Immunotherapy and BiomarkersChemotherapy-related skin toxicity

Cited by 449

The PROCLIPI international registry of early- stage mycosis fungoides identifies substantial diagnostic delay in most patients

Scarisbrick, J. J., Quaglino, P., Prince, H. M., Papadavid, E., Hodak, E., Bagot, M., Servitje, O., Berti, E., Ortiz‐Romero, P., Stadler, R., et al. (2019) · British Journal of Dermatology

Cutaneous lymphoproliferative disorders researchLymphoma Diagnosis and Treatment

Cited by 244

BRAF and MEK inhibitors increase PD-1-positive melanoma cells leading to a potential lymphocyte-independent synergism with anti-PD-1 antibody

Sanlorenzo, M., Vujic, I., Floris, A., Novelli, M., Gammaitoni, L., Giraudo, L., Macagno, M., Leuci, V., Rotolo, R., Donini, C., et al. (2018) · Clinical Cancer Research

Cancer Immunotherapy and BiomarkersMelanoma and MAPK Pathways

Cited by 47

Histological triage of early-stage mycosis fungoides using a weakly supervised deep learning-based model: a multicentre, external validation, and clinical utility study

Doeleman, T., Brussee, S., Valkema, P. A., Kempf, W., Vermeer, M. H., Kers, J., Wynaendts, L. C. D., Kerckhoffs, K. G. P., de Jonge, M. M., Nguyen, A. H., et al. (2026) · medRxiv

Cutaneous lymphoproliferative disorders researchAI in cancer detection

Cited by 0